Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial

Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company focused on developing innovative therapies for hearing loss disorders, has successfully completed patient enrollment for the first cohort in its…

Read MoreSensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial
Anebulo Pharmaceuticals

Anebulo Pharmaceuticals announces positive update and capital raise for Selonabant

Anebulo Pharmaceuticals announces positive update and capital raise for Selonabant Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on developing innovative treatments for acute cannabinoid-induced toxicities, has announced a positive regulatory update and the successful completion of a…

Read MoreAnebulo Pharmaceuticals announces positive update and capital raise for Selonabant

Refinancing plan unveiled by MultiPlan to strengthen its capital structure

Refinancing plan unveiled by MultiPlan to strengthen its capital structure MultiPlan Corporation (NYSE: MPLN), a prominent provider of technology and data solutions dedicated to cost management, quality improvement, and transparency in healthcare, has announced a comprehensive refinancing initiative. This refinancing…

Read MoreRefinancing plan unveiled by MultiPlan to strengthen its capital structure

Kidney disease: Proton Intelligence raises $6.95M for potassium monitoring trials

Kidney disease: Proton Intelligence raises $6.95M for potassium monitoring trials Proton Intelligence Inc., the developer of the innovative Continuous Potassium Monitoring (CKM™) platform, has successfully closed a $6.95 million USD Seed Financing round. The round was supported by investors including…

Read MoreKidney disease: Proton Intelligence raises $6.95M for potassium monitoring trials

Cervical Cancer: NERLYNX® Added to NCCN Guidelines for HER2-Mutation

Cervical Cancer : NERLYNX® Added to NCCN Guidelines for HER2-Mutation Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on advancing cancer treatments, has announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Cervical Cancer have been…

Read MoreCervical Cancer: NERLYNX® Added to NCCN Guidelines for HER2-Mutation

Hospital Unveils Promising Plans for a State-of-the-Art 50-Bed Rehabilitation Facility in Bangor

Hospital Unveils Promising Plans for a State-of-the-Art 50-Bed Rehabilitation Facility in Bangor Encompass Health Corp. (NYSE: EHC) has unveiled plans to construct a new 50-bed, freestanding inpatient rehabilitation hospital in Bangor, Maine, aimed at providing specialized care for patients recovering…

Read MoreHospital Unveils Promising Plans for a State-of-the-Art 50-Bed Rehabilitation Facility in Bangor